2 / 9
Page 12
allied
academies
Journal of Biomedical Research | Volume: 29
4
th
World Heart Congress
Molecular Biology, Tissue Science and Regenerative Medicine
International Conference on
Joint Event
&
November 19-20, 2018 | Paris, France
U
nder proper stimulation, mesenchymal stem cells (MSCs)
can be induced to differentiate intomyocytes, adipocytes,
osteoblasts, chondrocytes, tenocytes and hematopoietic-
supporting stroma .With recent reports thatMSCs derived from
bone marrow can differentiate into cardiac muscle
in vitro
and
in vivo
, MSCs autologous transplantation is a promising, new
therapeuticmodality for the repair ofmyocardial infarctions and
prevention of post-infarct congestive heart failure. However,
in experimental models, poor viability of the transplanted
cells is a major limiting factor of cell therapy. The survival rate
of transplanted cells into an uninjured mouse heart was very
low, 4 days post transplantation. This may require pro-survival
strategies to improve stemcell survival/number in the infarcted
heart. Although pro-survival strategies have been proven to be
successful in vitro, they actually may not solve the problems
of poor adhesion of MSCs. However, the major obstacle in the
clinical application of MSC-based therapy is the poor viability
of the transplanted cells due to harsh microenvironments
like ischemia, inflammation and/or anoikis in the infarcted
myocardium. Mesenchymal stemcells (MSCs) aremultipotent,
self-renewing cells harboring multi-lineage differentiation
potential and immunosuppressive properties that make them
an attractive candidate for biological cell-based regenerative
medicine. In addition to its undoubted clinical interest,
controlling the fateandbehaviorsofMSCs isacrucial prerequisite
for their therapeutic applications in regenerativemedicine. Stem
cell differentiation and modulation of functional activities are
generally controlled by “cocktails” of growth factors, signaling
molecules and/or genetic manipulations.
Speaker Biography
Ki-Chul Hwang is vice-president and Professor of College of Medicine, Catholic Kwandong
University and Director, Institute for Bio-Medical Convergence, International St. Mary’s
Hospital of Korea. He received his doctor of philosophy degree from the Korea University
in Republic of Korea and completed his Postdoctoral Fellowship at the Cleveland Clinic
Foundation, Cleveland, OH, USA and the Victor Chang Cardiac Research, NSW University,
Sydney, Australia. He has consecutively filled (Senior) Editorial Board at theWorld Journal
of Stem Cells, American Journal of Stem Cells and Journal of Geriatric Cardiology. Much
of his research career has focused on the adult stem cells and he is recognized to be at
the forefront of the emerging field about functional enhancement in stem cells and its
therapeutic role associated with many diseases.
e:
kchwang@cku.ac.krKi-Chul Hwang
Catholic Kwandong University, South Korea
Modification of mesenchymal stem cells for clinical application
Ki-Chul Hwang, Molecular Biology & Heart Congress 2018, Volume 29
DOI: 10.4066/biomedicalresearch-C8-022